European Commission approves Xtandi for high-risk BCR nmHSPC – The Cancer Letter
The European Commission has approved a label extension for Astellas Pharma’s Xtandi (enzalutamide) as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer who are unsuitable for salvage-radiotherapy. To access this subscriber-only content please log in or renew your subscription.Looking for IP […]